Kiniksa Pharmaceuticals International PLC Class A KNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
-
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
-
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
-
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
-
Kiniksa Pharmaceuticals Gets Orphan Drug Designation for KPL-387
Trading Information
- Previous Close Price
- $72.98
- Day Range
- $82.26–90.80
- 52-Week Range
- $35.20–90.80
- Bid/Ask
- $88.09 / $90.00
- Shares Outstanding
- 78.02M
- Market Cap
- $6.96B
- Volume/Avg
- 2M / 620,864
Key Statistics
- Price/Earnings (Normalized)
- 84.27
- Price/Sales
- 7.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.16%
Company Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 366
- Website
- https://www.kiniksa.com
Valuation
|
Metric
|
KNSA
|
|---|---|
Price/Earnings (Normalized) | 84.27 |
Price/Book Value | 9.80 |
Price/Sales | 7.85 |
Price/Cash Flow | 45.21 |
Price/Earnings
KNSA
Financial Strength
|
Metric
|
KNSA
|
|---|---|
Quick Ratio | 3.21 |
Current Ratio | 3.90 |
Interest Coverage | — |
Quick Ratio
KNSA
Profitability
|
Metric
|
KNSA
|
|---|---|
Return on Assets (Normalized) | 14.29% |
Return on Equity (Normalized) | 19.29% |
Return on Invested Capital (Normalized) | 18.98% |
Return on Assets
KNSA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|%KC!<^! | LOCK|!%tJ^ | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|Qwv?>%@ | LOCK|Tv@N | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|nv@Ls< | LOCK|#! | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|R^t%hP$l | LOCK|Xf | $32B | |||
| Viatris Inc
VTRS
| LOCK|&N?$RJ? | LOCK|YV# | $22B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|WCjb!Z | LOCK|!H< | $11B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|yMl | LOCK|zJH | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|tjymB!Z | LOCK|!l< | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|pJN%V%x | LOCK|TWz%! | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|dK!g$K | LOCK|sn | $2B |
United States